1. 403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors. (9th November 2020) Authors: Price, Timothy; Chawla, Sant; Falchook, Gerald; Prenen, Hans; Lugowska, Iwona; Subbiah, Vivek; Monzon, Jose; Ozawa, Yuichi; Arkenau, Tobias; Lima, Caio Rocha; Kuboki, Yasutoshi; Nishina, Tomohiro; Hui, Mun; Rasmussen, Erik; Wong, Hansen; Najmi, Saltanat; Sadraei, Nooshin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era. (18th March 2012) Authors: Allison, Daniel C.; Carney, Scott C.; Ahlmann, Elke R.; Hendifar, Andrew; Chawla, Sant; Fedenko, Alex; Angeles, Constance; Menendez, Lawrence R. Other Names: Casanova Jose Academic Editor. Journal: Sarcoma Issue: Volume 2012(2012) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. (20th April 2018) Authors: Bui, Nam; Kamat, Nikhil; Ravi, Vinod; Chawla, Sant; Lohman, Marti; Ganjoo, Kristen N Journal: Rare tumors Issue: Volume 10(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. (16th March 2023) Authors: Lin, Chenyu; Galal, Ahmed; Rizzieri, David; Chawla, Sant; Lee, Seung T.; Georgy, Angela; Dabovic, Kristina; Strack, Thomas; McKinney, Matthew Journal: Cancer investigation Issue: Volume 41:Number 3(2023) Page Start: 253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Issue 1 (December 2016) Authors: Gaston, Czar; Grimer, Robert; Parry, Michael; Stacchiotti, Silvia; Dei Tos, Angelo; Gelderblom, Hans; Ferrari, Stefano; Baldi, Giacomo; Jones, Robin; Chawla, Sant; Casali, Paolo; LeCesne, Axel; Blay, Jean-Yves; Dijkstra, Sander; Thomas, David; Rutkowski, Piotr Journal: Clinical sarcoma research Issue: Volume 6:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Issue 12 (December 2019) Authors: Chawla, Sant; Blay, Jean-Yves; Rutkowski, Piotr; Le Cesne, Axel; Reichardt, Peter; Gelderblom, Hans; Grimer, Robert J; Choy, Edwin; Skubitz, Keith; Seeger, Leanne; Schuetze, Scott M; Henshaw, Robert; Dai, Tian; Jandial, Danielle; Palmerini, Emanuela Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors. Issue 3 (16th November 2022) Authors: Zhou, Xiaofei; Richardson, Debra L.; Dowlati, Afshin; Goel, Sanjay; Sahebjam, Solmaz; Strauss, James; Chawla, Sant; Wang, Ding; Mould, Diane R.; Samnotra, Vivek; Faller, Douglas V.; Venkatakrishnan, Karthik; Gupta, Neeraj Journal: Clinical pharmacology in drug development Issue: Volume 12:Issue 3(2023) Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Eribulin in advanced liposarcoma and leiomyosarcoma. Issue 8 (3rd August 2017) Authors: Setola, Elisabetta; Noujaim, Jonathan; Benson, Charlotte; Chawla, Sant; Palmerini, Emanuela; Jones, Robin L. Journal: Expert review of anticancer therapy Issue: Volume 17:Issue 8(2017) Page Start: 717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Issue 10028 (16th April 2016) Authors: Schöffski, Patrick; Chawla, Sant; Maki, Robert G; Italiano, Antoine; Gelderblom, Hans; Choy, Edwin; Grignani, Giovanni; Camargo, Veridiana; Bauer, Sebastian; Rha, Sun Young; Blay, Jean-Yves; Hohenberger, Peter; D'Adamo, David; Guo, Matthew; Chmielowski, Bartosz; Le Cesne, Axel; Demetri, George D;... Journal: Lancet Issue: Volume 387:Issue 10028(2016) Page Start: 1629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. (1st May 2020) Authors: Baird, Kristin; Glod, John; Steinberg, Seth M.; Reinke, Denise; Pressey, Joseph G.; Mascarenhas, Leo; Federman, Noah; Marina, Neyssa; Chawla, Sant; Lagmay, Joanne P.; Goldberg, John; Milhem, Mohammed; Loeb, David M.; Butrynski, James E.; Turpin, Brian; Staddon, Arthur; Spunt, Sheri L.; Jones, Rob... Other Names: Kleinerman Eugenie S. Academic Editor. Journal: Sarcoma Issue: Volume 2020(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗